A settlement has been reached in a whistleblower class action lawsuit brought against Omnicare Inc who is accused of engaging in a kickback scheme in violation of the False Claims Act.
The settlement revolves both the civil accusations and criminal charges. However, the whistleblower in this case will receive a portion of the civil share amount totallying $397,925.
Filed in June 2011, the whistleblower lawsuit claims that Omnicare solicited and received kickbacks from the drug manufacturer Amgen Inc in return for implementing “therapeutic interchange” programs that were designed to switch Medicaid beneficiaries from a competitor drug to Amgen’s product Aranesp.